BioAtla (NASDAQ:BCAB) Announces Earnings Results

BioAtla (NASDAQ:BCAB) posted its earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.20, FiscalAI reports. The firm had revenue of $2.00 million during the quarter, compared to the consensus estimate of $0.70 million.

BioAtla Trading Up 4.5%

NASDAQ:BCAB traded up $0.01 during trading hours on Tuesday, hitting $0.16. 1,165,021 shares of the company were exchanged, compared to its average volume of 1,276,868. The stock has a market capitalization of $10.22 million, a price-to-earnings ratio of -0.14 and a beta of 1.08. BioAtla has a one year low of $0.13 and a one year high of $1.43. The company has a fifty day simple moving average of $0.20 and a 200 day simple moving average of $0.53.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Rodman & Renshaw started coverage on BioAtla in a report on Tuesday, January 13th. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BioAtla presently has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Investors Weigh In On BioAtla

A number of institutional investors have recently made changes to their positions in the stock. Woodline Partners LP bought a new stake in shares of BioAtla in the 1st quarter valued at $26,000. Jane Street Group LLC boosted its stake in BioAtla by 55.4% during the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after acquiring an additional 123,597 shares in the last quarter. Vanguard Group Inc. boosted its stake in BioAtla by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after acquiring an additional 162,647 shares in the last quarter. Susquehanna International Group LLP grew its holdings in BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in BioAtla in the fourth quarter worth $104,000. Institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.